Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study.
Joost J Breeksema, Alistair Niemeijer, Bouwe Kuin, Jolien Veraart, Jeanine Kamphuis, Nina Schimmel, Wim van den Brink, Eric Vermetten, Robert Schoevers
Frontiers in psychiatry January 1, 2022 DOI: 10.3389/fpsyt.2022.948115 via PubMed
Summary
AI-generated from the abstractPatients with treatment-resistant depression undergoing oral esketamine treatment often find the experience overwhelming and struggle with whether to let go or maintain control. Their ability to let go is influenced by preparation, emotional support, and the treatment setting. Better preparation, an optimized environment, and psychological support during sessions may improve patients' experiences and outcomes. The study provides recommendations for improving quality of care, including training for nurses and support staff.
Study at a glance
| Characteristics | Qualitative study Peer reviewed |
|---|---|
| Sample size | 17 |
| Population | Patients with treatment-resistant depression participating in off-label oral esketamine treatment |
| Intervention | oral esketamine |
| Duration | Six-week, twice-weekly esketamine treatment program, subsequently after six months of at-home use |
| Topics | Esketamine Ketamine Philosophy of mind |
| Keywords | Patient experience Set and setting Treatment-resistant depression trd Refractory depression |
| Citations | 41 |
| Key finding | Patients' ability to let go during esketamine sessions is influenced by preparation, emotional support, and setting, which may affect mood and treatment outcomes. |
Abstract
Ketamine and its enantiomer esketamine represent promising new treatments for treatment-resistant depression (TRD). Esketamine induces acute, transient psychoactive effects. How patients perceive esketamine treatment, and which conditions facilitate optimal outcomes, remains poorly understood. Understanding patient perspectives on these phenomena is important to identify unmet needs, which can be used to improve (es)ketamine treatments. To explore the perspectives of TRD patients participating in "off label" oral esketamine treatment. In-depth interviews were conducted with 17 patients (11 women) after a six-week, twice-weekly esketamine treatment program, and subsequently after six months of at-home use. Interviews explored participants' perspectives, expectations, and experiences with esketamine treatment. Audio interviews were transcribed verbatim and analysed following an Interpretative Phenomenological Analysis (IPA) framework. Key themes included overwhelming experiences; inadequate preparation; letting go of control; mood states influencing session experiences; presence and emotional support, and supportive settings. Patients' attempts to let go and give into vs. attempts to maintain control over occasionally overwhelming experiences was a central theme. Multiple factors influenced patients' ability to give into the experience and appeared to impact their mood and anxiety about future sessions, including level of preparation and education, physical and emotional support, and setting during the session. Better preparation beforehand, an optimized treatment setting, and emotional and psychological support during (es)ketamine sessions can help patients to "let go" and may lead to better quality of care and outcomes. Recommendations to improve quality of patient care in (es)ketamine treatment are provided, including suggestions for the training of nurses and other support staff.